Semaglyn Injection: India GLP-1 Guide
✓ Free to download
Learn about Semaglyn, a generic semaglutide injection by Zydus Lifesciences in India, including its dosing pen design and intended uses for diabetes and.
If your doctor has recently prescribed Semaglyn, you may be wondering how this injection works and whether it is right for you. That is completely normal. New medicines can feel confusing at first, especially injections. But Semaglyn is simpler to use than most people expect.
This guide explains what it is, how it works, and what to expect, in plain, everyday language.
What is Semaglyn?
Semaglyn is a brand name for semaglutide, a medicine belonging to the class called GLP-1 receptor agonists. It is developed by Zydus Lifesciences, one of India's leading pharmaceutical companies, and co-marketed with Lupin. It is approved by India's drug authority, the DCGI, for two conditions:
- Type 2 Diabetes: improving blood sugar control
- Chronic weight management: for adults with obesity or overweight with related health conditions
GLP-1 is a hormone your gut naturally releases after you eat. It signals your brain that you are full, slows digestion, and helps your body release the right amount of insulin at the right time.
Semaglyn mimics this natural hormone, but with a much longer-lasting effect. This means you feel less hungry, eat less, and your blood sugar stays more stable.
Zydus also markets semaglutide under two other brand names, MASHEMA and ALTERME. Under a licensing agreement signed in March 2026, Lupin co-markets the same Zydus semaglutide injection (15 mg/3 ml) and reusable pen under the names Semanext and Livarise.
The Semaglyn Reusable Adjustable Pen: The Key Differentiator
The most important thing to know about Semaglyn is its delivery device. Most semaglutide injections, including Ozempic and Wegovy, come as separate prefilled pens for each dose strength. As your dose increases, you need a new pen each time.
Semaglyn changes this completely.
The Semaglyn pen is a single reusable adjustable device:
- The medicine comes in a prefilled 15 mg/3 ml cartridge used in a reusable pen
- Zydus says the pen can deliver all strengths approved for type 2 diabetes and obesity
- You do not switch pens when your dose increases; you dial the dose your doctor prescribes
- Zydus holds exclusive rights to this pen technology in India
Zydus says this design lowers the overall cost of therapy and makes treatment simpler, especially for patients who need the therapy for months or years. Because the pen is dialled by hand, check the dose your doctor has prescribed each time and ask for a demonstration before your first injection.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, has described the device as designed to simplify treatment and support better long-term adherence.
How Semaglyn is Taken
Semaglyn is given as a subcutaneous injection, just under the skin, once a week, on the same day each week. Common injection sites are the stomach, the upper thigh, or the upper arm.
Your doctor will start you on a low dose and slowly increase it over several weeks. This gradual escalation helps your body adjust and reduces the chance of side effects.
Never change your dose on your own.
How Semaglyn Compares to Ozempic and Wegovy
| Feature | Semaglyn (Zydus) | Ozempic / Wegovy (Novo Nordisk) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Origin | Developed in India by Zydus | Denmark |
| Pen device | Reusable adjustable pen with prefilled cartridge | Prefilled disposable pens, each set to particular dose strengths |
| Dose flexibility | Multiple strengths, one pen | May need a different pen as the dose rises |
| Cost | Lower (Zydus estimate about Rs 2,200 a month at launch, March 2026) | Higher list price; Novo Nordisk cut starting-dose prices from April 2026 |
| Availability in India | Launched 21 March 2026, after patent expiry | Wegovy (weight management) since 2025; Ozempic (type 2 diabetes) since December 2025 |
The single adjustable pen is not just a convenience feature. According to reporting on the Zydus-Lupin partnership, this design is expected to lower treatment costs by allowing patients to use multiple doses from one device, a meaningful financial advantage for long-term therapy.
What Results Can You Expect and When?
Results vary between individuals and take time.
Weeks 1–4: Appetite may begin to reduce and you may feel full faster than usual. The starting dose is mainly to help your body get used to the medicine; it is not intended as a long-term dose for blood sugar control.
Month 2–3: As the dose increases, hunger reduces more noticeably. Many people start losing weight consistently. Blood sugar often improves meaningfully.
Month 4–6: Typically the period of biggest changes. Studies on semaglutide at higher doses show substantial weight loss and strong blood sugar control.
Beyond 6 months: Continued improvement with sustained lifestyle changes. Regular check-ins with your doctor help fine-tune the dose and diet plan.
Beyond weight and blood sugar, large trials found semaglutide lowered the risk of major cardiovascular events such as heart attack and stroke in people with established heart disease (SUSTAIN-6 in type 2 diabetes; SELECT in people with overweight or obesity without diabetes).
Common Side Effects
Like all medicines, Semaglyn can cause side effects. Most are mild and improve within the first few weeks.
- Nausea: the most common; often eases over a few weeks. Eating smaller meals helps.
- Vomiting: less common, usually brief
- Reduced appetite: the intended effect, which some find takes adjustment
- Loose stools or constipation: common in the early weeks
- Stomach discomfort or bloating: linked to slower gastric emptying
- Mild fatigue or headache: occasionally reported, usually in the first weeks
Serious side effects are uncommon. Get urgent medical help for:
- Severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis)
- Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (possible gallbladder problems)
- Vomiting or diarrhoea so severe you cannot keep fluids down (risk of dehydration and kidney injury)
- Swelling of the face, lips or throat, or trouble breathing (serious allergic reaction)
If you also take insulin or a sulfonylurea (such as glimepiride or gliclazide), your risk of low blood sugar is higher; your doctor may adjust those medicines. People with diabetic eye disease should report any change in vision. Tell your doctor before any surgery or procedure with anaesthesia or sedation.
Who Should Not Take Semaglyn?
Semaglyn is not suitable for everyone. Your doctor will screen you carefully. Avoid or use with caution if:
- Pregnant or breastfeeding: not recommended; inform your doctor if you are planning pregnancy
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome: must not be used
- Previous serious allergic reaction to semaglutide
- Past or current pancreatitis
- Severe kidney or liver disease
- Type 1 Diabetes: not approved for this
- Under 18 years of age: approved for adults only
Always give your doctor a full picture of your medical history, including all other medicines you take.
Why Semaglyn Matters for India
India is facing a serious and growing health challenge. According to the International Diabetes Federation (as cited in Zydus's February 2026 announcement), around 8.9 crore adults in India are living with diabetes. The same announcement reports that adult obesity prevalence has risen by 91% among women (from 12.6% to 24.0%) and by 146% among men (from 9.3% to 22.9%).
GLP-1 therapies like semaglutide have already transformed diabetes and obesity treatment globally. But until recently, they were largely inaccessible to Indian patients because of cost and limited availability.
The Zydus-Lupin collaboration aims to address this gap by combining Zydus' development capabilities with Lupin's marketing reach. Lower-priced, India-made semaglutide is a meaningful step toward making this treatment more accessible.
Tracking Your Progress on Semaglyn
Managing weight or blood sugar is a long-term effort. Keeping a consistent weekly log of your weight, fasting sugar, injection day, and symptoms helps your doctor make better decisions at each visit.
Weight Easy supports semaglutide tracking for Indian users, log your dose, weekly weight, side effects, and meal patterns in one place to get the clearest picture of how your treatment is working.
Final Takeaway
Semaglyn is Zydus Lifesciences' generic semaglutide, approved in India for type 2 diabetes and weight management. Its standout feature is a reusable adjustable pen that Zydus says can deliver all approved dose strengths, which may make treatment simpler and lower-cost. Results take time but are meaningful when combined with diet and exercise.
Consult your healthcare provider before starting any medication.
Sources
- Zydus Lifesciences. Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry. 25 February 2026: https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-plans-to-launch-innovative-Semaglutide-Injection-in-India-on-Day-1-of-patent-expiry--expanding-patient-access-to-GLP-1-therapy.pdf
- BioSpectrum India. Zydus launches Semaglutide Injection in reusable multi-dose pen device in India. 21 March 2026: https://biospectrumindia.com/news/16/27523/zydus-launches-semaglutide-injection-in-reusable-multi-dose-pen-device-in-india.html
- Lupin Limited. Lupin and Zydus sign licensing agreement for co-marketing innovative semaglutide injection in India. 17 March 2026: https://www.lupin.com/media/press-releases/lupin-and-zydus-sign-licensing-agreement-for-co-marketing-innovative-semaglutide-injection-in-india
- BioSpectrum India. Novo Nordisk India sets price for starting dose of Ozempic and Wegovy. 31 March 2026: https://biospectrumindia.com/news/16/27598/novo-nordisk-india-sets-patient-centred-price-of-rs-202-day-for-starting-dose-of-ozempic-and-wegovy.html
- Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- Wegovy U.S. prescribing information (revised June 2026): https://www.novo-pi.com/wegovy.pdf
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM 2016: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023: https://doi.org/10.1056/NEJMoa2307563
Related Articles
- Obeda: India's Generic Semaglutide from Dr. Reddy's
- Track the dose cycle of your prescribed medicine
- Sematrinity by Sun Pharma: India GLP-1 Guide
- Lupin Limited. Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India. March 2026. Lupin Press Release
- International Diabetes Federation. IDF Diabetes Atlas, 11th Edition. 2025. idf.org
- Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery. 2025. https://doi.org/10.1038/s41573-025-01183-8
- ICMR-INDIAB-17. Metabolic non-communicable disease health report of India. Lancet Diabetes Endocrinol. 2023
FAQ
What is Semaglyn?
Semaglyn is a generic semaglutide injection developed by Zydus Lifesciences and co-marketed with Lupin in India. It is approved by the DCGI for type 2 diabetes and chronic weight management. Its key feature is a single reusable adjustable pen that covers multiple dose strengths.
How is Semaglyn different from Ozempic?
Both contain semaglutide - the same active molecule. Semaglyn is developed in India by Zydus and is priced lower (Zydus estimated an average of about Rs 2,200 a month at its March 2026 launch). Its standout feature is the reusable pen with prefilled cartridges, which can deliver different dose strengths, whereas each Ozempic or Wegovy pen is set to particular dose strengths.
How does the Semaglyn reusable pen work?
The Semaglyn pen is an adjustable, reusable device used with prefilled 15 mg/3 ml semaglutide cartridges. Zydus says it can deliver all strengths approved for type 2 diabetes and obesity, so when your doctor increases your dose you dial the new dose on the same pen instead of buying a different pen. Zydus holds exclusive rights to this pen technology in India.
What are Semaglyn's side effects?
The most common side effects are nausea, vomiting, diarrhoea, constipation, and reduced appetite - consistent with the GLP-1 class. These are usually mild to moderate and often ease over the first few weeks. Serious side effects such as pancreatitis and gallbladder problems are uncommon; get urgent medical help for severe, persistent stomach pain that may spread to the back, or vomiting that stops you keeping fluids down.
Is Semaglyn affordable in India?
Generally, yes. At its March 2026 launch Zydus estimated an average monthly cost of about Rs 2,200, below the list price of Ozempic or Wegovy. Zydus says the reusable pen lowers overall cost because you do not need a new pen strength as your dose changes. Prices change, so check the current MRP with your pharmacist.
Written by
Dietician / Nutritionist
Health Content Writer
Lakshmi Devi G is a Dietician / Nutritionist professional who contributes evidence-informed health and wellness content for Weight Easy.
View profile →Reviewed by
BDS / MDS
Senior Medical Reviewer
Jude Bencia is a BDS / MDS professional who reviews Weight Easy health content for medical and editorial accuracy.
View profile →